

**UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF NEW JERSEY**

IN RE LUMIFY

Civil Action No. 21-16766 (RK) (RLS)
(CONSOLIDATED)

**ORDER GRANTING
MOTION TO STAY**

THIS MATTER having been brought before the Court by Defendants Dr. Reddy's Laboratories, Inc., Dr. Reddy's Laboratories S.A., Slayback Pharma LLC, and Slayback Pharma India LLP (collectively, "Defendants") on a Motion to Stay this matter pending resolution of two *Inter Partes* Review ("IPR") proceedings before the Patent Trial and Appeal Board ("PTAB"), (Doc. No. 410); and Plaintiffs Bausch & Lomb, Inc., Bausch & Lomb Ireland Limited, and Eye Therapies, LLC (collectively, "Plaintiffs") having opposed the Motion, (Doc. No. 411); and the Court having fully considered the submissions of the parties without oral argument pursuant to Federal Rule of Civil Procedure 78 and Local Civil Rule 78.1(b); and for the reasons set forth in the Court's November 27, 2024 Memorandum Opinion, and for good cause shown,

IT IS on this **27th** day of **November 2024** hereby

ORDERED that Defendants' Motion to Stay (Doc. No. 410) is **GRANTED**; and it is further

ORDERED that all proceedings in this matter are hereby **STAYED** pending resolution of the IPR proceedings before the PTAB and further order of this Court; and it is further

ORDERED that the parties shall file a joint status letter as to proceedings before the PTAB and/or the United States Court of Appeals for the Federal Circuit by no later than **May 1, 2025**; and it is further

ORDERED that the Clerk of the Court shall **TERMINATE** the Motion pending at Docket Entry Number 410; and it is further

ORDERED that, exercising the Court's discretion to manage its own docket, the Clerk of the Court shall **ADMINISTRATIVELY CLOSE** this matter pending the stay.

SO ORDERED.

/s/ Rukhsanah L. Singh
RUKHSANAH L. SINGH
UNITED STATES MAGISTRATE JUDGE